{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:51:21Z","timestamp":1785840681407,"version":"3.56.0"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AREA-R15"],"award-info":[{"award-number":["AREA-R15"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["1R15HL138606-01A1"],"award-info":[{"award-number":["1R15HL138606-01A1"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010937","name":"St. John's University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.lfs.2022.120716","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T20:46:54Z","timestamp":1655153214000},"page":"120716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Repurposing therapeutics for malignant pleural mesothelioma (MPM) \u2013 Updates on clinical translations and future outlook"],"prefix":"10.1016","volume":"304","author":[{"given":"Nishant S.","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2022.120716_bb0005","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1183\/16000617.0063-2016","article-title":"Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment","volume":"25","author":"Bibby","year":"2016","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.lfs.2022.120716_bb0010","doi-asserted-by":"crossref","first-page":"753","DOI":"10.5858\/arpa.2017-0365-RA","article-title":"Malignant mesothelioma and its non-Asbestos causes","volume":"142","author":"Attanoos","year":"2018","journal-title":"Arch Pathol Lab Med."},{"key":"10.1016\/j.lfs.2022.120716_bb0015","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.3390\/ijms21176306","article-title":"Repurposing quinacrine for treatment of malignant mesothelioma: in-vitro therapeutic and mechanistic evaluation","volume":"21","author":"Kulkarni","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2022.120716_bb0020","author":"Selby"},{"key":"10.1016\/j.lfs.2022.120716_bb0025","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1096\/fba.2019-00040","article-title":"Zeolites ameliorate asbestos toxicity in a transgenic model of malignant mesothelioma","volume":"1","author":"Fan","year":"2019","journal-title":"FASEB BioAdvances."},{"key":"10.1016\/j.lfs.2022.120716_bb0030","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ebiom.2019.09.003","article-title":"Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions","volume":"48","author":"Alcala","year":"2019","journal-title":"EBioMedicine."},{"key":"10.1016\/j.lfs.2022.120716_bb0035","doi-asserted-by":"crossref","first-page":"924","DOI":"10.21037\/tlcr.2020.03.38","article-title":"Clinical significance of histologic subtyping of malignant pleural mesothelioma","volume":"9","author":"Brcic","year":"2020","journal-title":"Transl Lung Cancer Res."},{"key":"10.1016\/j.lfs.2022.120716_bb0040","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtcvs.2012.12.037","article-title":"Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection","volume":"145","author":"Sugarbaker","year":"2013","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lfs.2022.120716_bb0045","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/thoraxjnl-2013-204161","article-title":"Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis","volume":"69","author":"Reid","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.lfs.2022.120716_bb0050","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/ajim.4700030305","article-title":"Occupational exposure to asbestos: population at risk and projected mortality-1980\u20132030","volume":"3","author":"Nicholson","year":"1982","journal-title":"Am. J. Ind. Med."},{"key":"10.1016\/j.lfs.2022.120716_bb0055","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/bmb\/ldp047","article-title":"Malignant mesothelioma","volume":"93","author":"Rudd","year":"2010","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.lfs.2022.120716_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203003","article-title":"BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state","volume":"13","author":"Rath","year":"2018","journal-title":"PLoS ONE."},{"key":"10.1016\/j.lfs.2022.120716_bb0065","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fonc.2020.00343","article-title":"Emerging treatments for malignant pleural mesothelioma: where are we heading?","volume":"10","author":"Cantini","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0070","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0080","author":"Heather Von St. James"},{"key":"10.1016\/j.lfs.2022.120716_bb0085","author":"Selby"},{"key":"10.1016\/j.lfs.2022.120716_bb0090","doi-asserted-by":"crossref","first-page":"S285","DOI":"10.21037\/jtd.2017.10.16","article-title":"Surgery for malignant pleural mesothelioma: an international guidelines review","volume":"10","author":"Ricciardi","year":"2018","journal-title":"J Thorac Dis."},{"key":"10.1016\/j.lfs.2022.120716_bb0095","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.jtho.2018.08.001","article-title":"Surgery in malignant pleural mesothelioma","volume":"13","author":"Bueno","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0100","doi-asserted-by":"crossref","first-page":"285","DOI":"10.21037\/tlcr.2017.05.04","article-title":"Intraoperative adjuncts for malignant pleural mesothelioma","volume":"6","author":"Chan","year":"2017","journal-title":"Transl Lung Cancer Res."},{"key":"10.1016\/j.lfs.2022.120716_bb0105","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.2005.04.6813","article-title":"Phase I to II study of Pleurectomy\/Decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma","volume":"24","author":"Richards","year":"2006","journal-title":"JCO."},{"key":"10.1016\/j.lfs.2022.120716_bb0110","article-title":"Asbestos exposure and mesothelioma mortality among atomic veterans","volume":"1\u201315","author":"Till","year":"2018","journal-title":"Int. J. Radiat. Biol."},{"key":"10.1016\/j.lfs.2022.120716_bb0115","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2217\/imt-2016-0123","article-title":"Anti-CTLA-4 therapy for malignant mesothelioma","volume":"9","author":"Guazzelli","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.lfs.2022.120716_bb0120","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/14712598.2020.1703945","article-title":"Nivolumab for the treatment of unresectable pleural mesothelioma","volume":"20","author":"Hotta","year":"2020","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.lfs.2022.120716_bb0125","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2022.120716_bb0130","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/14712598.2019.1606209","article-title":"Immune checkpoint inhibition for the treatment of mesothelioma","volume":"19","author":"Nowak","year":"2019","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.lfs.2022.120716_bb0135","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.omto.2020.01.009","article-title":"Antimesothelioma immunotherapy by CTLA-4 blockade depends on active PD1-based TWIST1 vaccination","volume":"16","author":"Tan","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.lfs.2022.120716_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000461","article-title":"Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma","volume":"8","author":"Hotta","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lfs.2022.120716_bb0145","author":"USFDA"},{"key":"10.1016\/j.lfs.2022.120716_bb0150","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/j.lfs.2022.120716_bb0155","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/S1470-2045(19)30532-7","article-title":"Tumour treating fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial","volume":"20","author":"Ceresoli","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0160","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.drudis.2015.05.001","article-title":"Drug repositioning and repurposing: terminology and definitions in literature","volume":"20","author":"Langedijk","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.lfs.2022.120716_bb0165","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"Drug repurposing: a promising tool to accelerate the drug discovery process","volume":"24","author":"Parvathaneni","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.lfs.2022.120716_bb0170","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2022.120716_bb0175","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bph.13798","article-title":"Drug repurposing from the perspective of pharmaceutical companies","volume":"175","author":"Cha","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2022.120716_bb0180","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrd2030","article-title":"Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond","volume":"5","author":"Ghofrani","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2022.120716_bb0185","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/2040620711413165","article-title":"The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development","volume":"2","author":"Rehman","year":"2011","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.lfs.2022.120716_bb0190","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.lfs.2022.120716_bb0195","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(13)70125-6","article-title":"Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study","volume":"14","author":"Buikhuisen","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0200","doi-asserted-by":"crossref","DOI":"10.1177\/2036361319863498","article-title":"Costs of medical care for mesothelioma","volume":"11","author":"Borrelli","year":"2019","journal-title":"Rare Tumors."},{"key":"10.1016\/j.lfs.2022.120716_bb0205","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0098-2017","article-title":"Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?","volume":"27","author":"Boyer","year":"2018","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.lfs.2022.120716_bb0210","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3332\/ecancer.2018.886","article-title":"ReDO_DB: the repurposing drugs in oncology database","volume":"12","author":"Pantziarka","year":"2018","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.lfs.2022.120716_bb0215","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0220","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.lungcan.2019.09.010","article-title":"Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma","volume":"137","author":"Takeda","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lfs.2022.120716_bb0225","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jtho.2018.04.032","article-title":"A phase I trial of surgical resection and intraoperative hyperthermic cisplatin and gemcitabine for pleural mesothelioma","volume":"13","author":"Burt","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0230","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0235","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s40883-018-0077-8","article-title":"Evaluating angiogenic potential of small molecules using genetic network approaches","volume":"5","author":"Das","year":"2019","journal-title":"Regen. Eng. Transl. Med."},{"key":"10.1016\/j.lfs.2022.120716_bb0240","first-page":"133","article-title":"Development of small molecules targeting the wnt signaling pathway in cancer stem cells for the treatment of colorectal cancer","volume":"14","author":"Song","year":"2015","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.lfs.2022.120716_bb0245","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cytogfr.2019.10.005","article-title":"Novel activators and small-molecule inhibitors of STAT3 in cancer","volume":"49","author":"Yang","year":"2019","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.lfs.2022.120716_bb0250","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0140-6736(14)60795-9","article-title":"Surgical resection of mesothelioma: an evidence-free practice","volume":"384","author":"Lee","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2022.120716_bb0255","doi-asserted-by":"crossref","first-page":"8517","DOI":"10.1200\/JCO.2019.37.15_suppl.8517","article-title":"Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: cancer and leukemia group B (CALGB) 30901 (Alliance)","volume":"37","author":"Dudek","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.lfs.2022.120716_bb0260","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1111\/1759-7714.13490","article-title":"Amrubicin in previously treated patients with malignant pleural mesothelioma: a phase II study","volume":"11","author":"Ikeda","year":"2020","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.lfs.2022.120716_bb0265","first-page":"39","article-title":"A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma","volume":"8","author":"Jamil","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lfs.2022.120716_bb0270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","article-title":"Bisphosphonates: preclinical review","volume":"9","author":"Green","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.lfs.2022.120716_bb0275","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.11128","article-title":"Antitumor effects of bisphosphonates","volume":"97","author":"Green","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.lfs.2022.120716_bb0280","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jbo.2013.12.001","article-title":"The anti-tumour effects of zoledronic acid","volume":"3","author":"Zekri","year":"2014","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0285","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1365-2141.1997.2713086.x","article-title":"Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity","volume":"98","author":"Shipman","year":"1997","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lfs.2022.120716_bb0290","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2184.2011.00745.x","article-title":"Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line","volume":"44","author":"Di Salvatore","year":"2011","journal-title":"Cell Prolif."},{"key":"10.1016\/j.lfs.2022.120716_bb0295","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.cellbi.2007.02.004","article-title":"Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study","volume":"31","author":"Ozturk","year":"2007","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.lfs.2022.120716_bb0300","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/sj.bjc.6605814","article-title":"Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma","volume":"103","author":"Veltman","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lfs.2022.120716_bb0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060297","article-title":"Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53 expression levels","volume":"8","author":"Okamoto","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2022.120716_bb0310","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.18632\/oncotarget.2731","article-title":"Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma","volume":"6","author":"Salaroglio","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2022.120716_bb0315","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/jnci\/djt210","article-title":"Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer","volume":"105","author":"Kang","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.lfs.2022.120716_bb0320","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv123","article-title":"Targeting focal adhesion kinase and resistance to mTOR inhibition in pancreatic neuroendocrine tumors","volume":"107","author":"Fran\u00e7ois","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.lfs.2022.120716_bb0325","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12931-019-1244-2","article-title":"Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer","volume":"20","author":"Tong","year":"2019","journal-title":"Respir. Res."},{"key":"10.1016\/j.lfs.2022.120716_bb0330","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.lfs.2022.120716_bb0335","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s10637-015-0282-y","article-title":"A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors","volume":"33","author":"Jones","year":"2015","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.lfs.2022.120716_bb0340","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","article-title":"Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND-A double-blind, randomized, phase II study","volume":"37","author":"Fennell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0345","author":"Povtak"},{"key":"10.1016\/j.lfs.2022.120716_bb0350","author":"Clinicaltrials.gov"},{"key":"10.1016\/j.lfs.2022.120716_bb0355","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1097\/JTO.0b013e318174e910","article-title":"The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies","volume":"3","author":"Nikolinakos","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0360","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s10637-013-9991-2","article-title":"Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized phase II study","volume":"31","author":"Hyams","year":"2013","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.lfs.2022.120716_bb0365","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1517\/13543780903183528","article-title":"Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma","volume":"18","author":"Dietrich","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.lfs.2022.120716_bb0370","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s10637-014-0106-5","article-title":"A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients","volume":"32","author":"Spreafico","year":"2014","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.lfs.2022.120716_bb0375","doi-asserted-by":"crossref","first-page":"5582648","DOI":"10.1155\/2021\/5582648","article-title":"Cediranib induces apoptosis, G1 phase cell cycle arrest, and autophagy in non-small-cell lung cancer cell A549 in vitro","volume":"2021","author":"Guo","year":"2021","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.lfs.2022.120716_bb0380","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jtho.2017.05.021","article-title":"Phase I trial of cediranib in combination with cisplatin and pemetrexed in chemonaive patients with unresectable malignant pleural mesothelioma (SWOG S0905)","volume":"12","author":"Tsao","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0385","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1200\/JCO.19.00269","article-title":"Phase II trial of cediranib in combination with cisplatin and pemetrexed in chemotherapy-Na\u00efve patients with unresectable malignant pleural mesothelioma (SWOG S0905)","volume":"37","author":"Tsao","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0390","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18102021","article-title":"Angiogenesis inhibitors in NSCLC","volume":"18","author":"Manzo","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2022.120716_bb0395","first-page":"126","article-title":"Antiangiogeneic strategies in mesothelioma","volume":"10","author":"Nowak","year":"2020","journal-title":"FrontOncologia"},{"key":"10.1016\/j.lfs.2022.120716_bb0400","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cyto.2018.08.006","article-title":"Role of angiopoietins in mesothelioma progression","volume":"118","author":"Magkouta","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.lfs.2022.120716_bb0405","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1158\/1078-0432.CCR-17-1507","article-title":"Nintedanib is active in malignant pleural mesothelioma cell models and inhibits angiogenesis and tumor growth in vivo","volume":"24","author":"Laszlo","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2022.120716_bb0410","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lfs.2022.120716_bb0415","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib plus Pemetrexed\/Cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomizedPlacebo-Controlled LUME-Meso Trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0420","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2017.205","article-title":"Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models","volume":"117","author":"Belgiovine","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lfs.2022.120716_bb0425","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211020529","article-title":"An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer","volume":"13","author":"Patel","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0430","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1158\/1078-0432.CCR-12-1513","article-title":"Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer","volume":"18","author":"Vidal","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2022.120716_bb0435","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1093\/annonc\/mdx357","article-title":"Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study","volume":"28","author":"Calvo","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0440","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.lungcan.2016.07.012","article-title":"Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: report of two cases","volume":"102","author":"Metaxas","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lfs.2022.120716_bb0445","author":"USFDA"},{"key":"10.1016\/j.lfs.2022.120716_bb0450","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.annonc.2019.12.009","article-title":"Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-Centre, single-arm, phase II trial (SAKK 17\/16)","volume":"31","author":"Metaxas","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0455","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0460","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1634\/theoncologist.2014-0465","article-title":"Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor","volume":"20","author":"Zhao","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.lfs.2022.120716_bb0465","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.lfs.2022.120716_bb0470","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0140-6736(21)00147-1","article-title":"Immune checkpoint inhibitors in mesothelioma: a turning point","volume":"397","author":"Ceresoli","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2022.120716_bb0475","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3390\/molecules24061190","article-title":"Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology","volume":"24","author":"Lee","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2022.120716_bb0480","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","article-title":"Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the bio-MAPS cohort","volume":"20","author":"Brosseau","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lfs.2022.120716_bb0490","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jtho.2018.05.015","article-title":"Nivolumab plus erlotinib in patients with EGFR-mutant advanced NSCLC","volume":"13","author":"Gettinger","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0495","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.pharmthera.2014.11.017","article-title":"The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience","volume":"148","author":"Berman","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2022.120716_bb0500","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0505","doi-asserted-by":"crossref","first-page":"e705","DOI":"10.1016\/j.cllc.2018.05.001","article-title":"A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: a study protocol","volume":"19","author":"Fujimoto","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lfs.2022.120716_bb0510","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the european thoracic oncology platform (ETOP 9\u201315) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0515","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2022.120716_bb0520","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0525","unstructured":"Uri Weinberg. Novocure\u2019s Tumor Treating Fields: Innovative brain cancer therapy with survival and safety benefits [Internet]. Nature Portfolio. Available from: https:\/\/www.nature.com\/articles\/d42473-018-00156-3."},{"key":"10.1016\/j.lfs.2022.120716_bb0530","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2022.120716_bb0535","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2022.120716_bb0540","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"Forde","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2022.120716_bb0545","author":"Clinicaltrials.gov"},{"key":"10.1016\/j.lfs.2022.120716_bb0550","author":"Clinicaltrials.gov"},{"key":"10.1016\/j.lfs.2022.120716_bb0555","author":"Clinicaltrials.gov"},{"key":"10.1016\/j.lfs.2022.120716_bb0560","doi-asserted-by":"crossref","first-page":"7391","DOI":"10.1002\/jcp.26579","article-title":"Possible repurposing of pyrvinium pamoate for the treatment of mesothelioma: a pre-clinical assessment","volume":"233","author":"Barbarino","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.lfs.2022.120716_bb0565","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijbiomac.2020.05.146","article-title":"Metformin-loaded chitosomes for treatment of malignant pleural mesothelioma \u2013 a rare thoracic cancer","volume":"160","author":"Shukla","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.lfs.2022.120716_bb0570","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3390\/pharmaceutics11110559","article-title":"Metformin-encapsulated liposome delivery system: an effective treatment approach against breast cancer","volume":"11","author":"Shukla","year":"2019","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.lfs.2022.120716_bb0575","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12967-017-1158-z","article-title":"FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model","volume":"15","author":"Szymiczek","year":"2017","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.lfs.2022.120716_bb0580","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.neo.2017.05.003","article-title":"Combined inhibition of CDK4\/6 and PI3K\/AKT\/mTOR pathways induces a synergistic anti-tumor effect in malignant pleural mesothelioma cells","volume":"19","author":"Bonelli","year":"2017","journal-title":"Neoplasia"},{"key":"10.1016\/j.lfs.2022.120716_bb0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00124","article-title":"Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: results from the targeted agent and profiling utilization registry study","author":"Al Baghdadi","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0590","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.athoracsur.2016.08.071","article-title":"Extended pleurectomy-decortication\u2013based treatment for advanced stage epithelial mesothelioma yielding a median survival of nearly three years","volume":"103","author":"Friedberg","year":"2017","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lfs.2022.120716_bb0595","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jtho.2018.08.2036","article-title":"Current and future management of malignant mesothelioma: a consensus report from the National Cancer Institute thoracic malignancy steering committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation","volume":"13","author":"Tsao","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lfs.2022.120716_bb0600","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1273302","article-title":"CAR T-cell intrinsic PD-1 checkpoint blockade: a two-in-one approach for solid tumor immunotherapy","volume":"6","author":"Chen","year":"2017","journal-title":"OncoImmunology"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522004167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522004167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:00:58Z","timestamp":1758402058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320522004167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":118,"alternative-id":["S0024320522004167"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2022.120716","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing therapeutics for malignant pleural mesothelioma (MPM) \u2013 Updates on clinical translations and future outlook","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2022.120716","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120716"}}